|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.255 USD | +1.79% |
|
+5.02% | +18.70% |
| 01-05 | Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH | CI |
| 01-05 | Altimmune Says US FDA Grants Breakthrough Therapy Designation for Pemvidutide in MASH | MT |
| Capitalization | 456M 393M 366M 341M 634M 41.22B 680M 4.21B 1.66B 19.71B 1.71B 1.68B 72.3B | P/E ratio 2025 * |
-4.26x | P/E ratio 2026 * | -3.24x |
|---|---|---|---|---|---|
| Enterprise value | 379M 326M 304M 283M 526M 34.2B 564M 3.49B 1.37B 16.35B 1.42B 1.39B 59.98B | EV / Sales 2025 * |
97,306x | EV / Sales 2026 * | 168,849x |
| Free-Float |
99.21% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Altimmune, Inc.
More recommendations
More press releases
More news
| 1 day | +1.79% | ||
| 1 week | +5.02% | ||
| Current month | +18.70% | ||
| 1 month | -18.84% | ||
| 3 months | +7.12% | ||
| 6 months | +2.51% | ||
| Current year | +18.70% |
| 1 week | 3.96 |  | 4.4 |
| 1 month | 3.48 | | 5.36 |
| Current year | 3.48 | | 4.53 |
| 1 year | 2.9 | | 7.73 |
| 3 years | 2.09 | | 16.35 |
| 5 years | 2.09 | | 24.61 |
| 10 years | 1.51 | | 237.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jerome Durso
CEO | Chief Executive Officer | 58 | 2025-12-31 |
Gregory Weaver
DFI | Director of Finance/CFO | 70 | 2024-11-10 |
| Chief Tech/Sci/R&D Officer | 64 | 2025-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Philip Hodges
BRD | Director/Board Member | 58 | 2003-08-31 |
Mitchel Sayare
CHM | Chairman | 78 | 2017-12-31 |
Klaus Schafer
BRD | Director/Board Member | 76 | 2012-06-30 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.79% | +5.02% | -34.88% | -71.36% | 456M | |
| +0.90% | 0.00% | +8.53% | +90.02% | 49.27B | |
| +0.15% | +5.63% | +88.29% | +13.80% | 44.15B | |
| -2.81% | -6.20% | +127.50% | +735.28% | 34.86B | |
| -2.61% | +7.57% | -6.45% | -25.74% | 27.38B | |
| +0.05% | +10.80% | +127.39% | -44.88% | 21.21B | |
| -3.86% | +0.65% | +45.67% | -22.49% | 21.63B | |
| +0.86% | -0.72% | +176.87% | - | 13.95B | |
| -1.22% | -5.65% | +114.99% | +150.31% | 14.58B | |
| -0.96% | -7.70% | -4.51% | +278.65% | 13.61B | |
| Average | -0.80% | +0.59% | +64.34% | +122.62% | 24.11B | |
| Weighted average by Cap. | -0.92% | +0.99% | +67.78% | +151.82% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.89K 3.35K 3.12K 2.91K 5.4K 351K 5.8K 35.88K 14.12K 168K 14.59K 14.29K 616K | 2.22K 1.91K 1.78K 1.66K 3.08K 201K 3.31K 20.48K 8.06K 95.89K 8.32K 8.15K 352K |
| Net income | -84.85M -73.09M -68.11M -63.37M -118M -7.67B -126M -783M -308M -3.67B -318M -312M -13.45B | -126M -108M -101M -93.82M -175M -11.35B -187M -1.16B -456M -5.43B -471M -461M -19.91B |
| Net Debt | -77.75M -66.97M -62.41M -58.06M -108M -7.02B -116M -717M -282M -3.36B -292M -286M -12.32B | -81.42M -70.14M -65.36M -60.81M -113M -7.36B -121M -751M -296M -3.52B -305M -299M -12.9B |
More financial data
* Estimated data
Employees
59
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-15 | 4.285 $ | +2.51% | 3,687,147 |
| 26-01-14 | 4.180 $ | +4.24% | 3,266,539 |
| 26-01-13 | 4.010 $ | -0.99% | 2,604,176 |
| 26-01-12 | 4.050 $ | +0.75% | 2,763,838 |
| 26-01-09 | 4.020 $ | -1.47% | 3,075,210 |
Delayed Quote Nasdaq, January 15, 2026 at 03:14 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
4.180USD
Average target price
17.75USD
Spread / Average Target
+324.64%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALT Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition